Literature DB >> 16845327

Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma.

Michele Guida1, Angela Riccobon, Guido Biasco, Alessandra Ravaioli, Addolorata Casamassima, Andrea Freschi, Maurizio Dalla Palma, Enzo Galligioni, Rolando Nortilli, Vanna Chiarion-Sileni, Jacopo Picozzo, Antonella Romanini, Oriana Nanni, Ruggero Ridolfi.   

Abstract

Cytokines play a crucial role in the host's immune response. In melanoma patients, cytokine profiles seems to be related to the clinical course and their imbalance could be associated to tumour progression. Thus, we studied a panel of baseline cytokines and their behaviour during treatment in order to verify their correlation with clinical outcomes. Interleukin-6, interleukin-8, interleukin-10, interleukin-12 and soluble receptor of interleukin-2 were evaluated in 90 out of 176 metastatic melanoma patients enrolled in a phase III study comparing chemotherapy and biochemotherapy. We divided patients into three different groups according to their own cytokine levels (low, intermediate and high) and then we correlated these groups with some clinical features. We also monitored the cytokines during the treatment in a subgroup of 37 patients. In univariate analysis, higher values of interleukin-6 (P = 0.005), soluble receptor of interleukin-2 (P = 0.001) and interleukin-12 (P = 0.010) were correlated with a worse survival. Conversely, interleukin-8 was unable to discriminate patients with different prognoses, and interleukin-10 was undetectable in the majority of patients. In multivariate analysis, only soluble receptor of interleukin-2 maintained its independent role in survival. The impact of baseline cytokines on response was insignificant. Regarding the behaviours of cytokines during treatment, the most remarkable aspect was a progressive increase of interleukin-12 and soluble receptor of interleukin-2 in patients with a better survival. In our metastatic melanoma patients, higher basal levels of interleukin-6, interleukin-12 and soluble receptor of interleukin-2 were associated with a worse survival. In contrast, a progressive increase of interleukin-12 and soluble receptor of interleukin-2 was observed during treatment in patients with a better survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845327     DOI: 10.1097/01.cmr.0000200491.00841.5f

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  4 in total

1.  Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors.

Authors:  Michele Guida; Addolorata Casamassima; Giulia Monticelli; Michele Quaranta; Giuseppe Colucci
Journal:  J Transl Med       Date:  2007-10-22       Impact factor: 5.531

2.  Immune parameters in the prognosis and therapy monitoring of cutaneous melanoma patients: experience, role, and limitations.

Authors:  Monica Neagu; Carolina Constantin; Sabina Zurac
Journal:  Biomed Res Int       Date:  2013-09-19       Impact factor: 3.411

Review 3.  Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis.

Authors:  Bodo E Lippitz; Robert A Harris
Journal:  Oncoimmunology       Date:  2016-05-11       Impact factor: 8.110

4.  Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study.

Authors:  Jan Kučera; Karolína Strnadová; Barbora Dvořánková; Lukáš Lacina; Ivana Krajsová; Jiří Štork; Hana Kovářová; Helena Kupcová Skalníková; Petr Vodička; Jan Motlík; Pavel Dundr; Karel Smetana; Ondřej Kodet
Journal:  Oncol Rep       Date:  2019-09-17       Impact factor: 3.906

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.